| Revue: | Brazilian Journal of Pharmaceutical Sciences |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000451702 |
| ISSN: | 1984-8250 |
| Autores: | Ribeiro, Anita Eugenia Alencar Santos1 Ferreira, Eliane Feitosa1 Leal, Jaknea dos Santos1 Barberino, Ricássio de Sousa2 Oliveira, Helinando Pequeno de3 Palheta-Junior, Raimundo Campos1 |
| Instituciones: | 1Universidade Federal do Vale do Sao Francisco, Laboratorio de Farmacologia Veterinaria, Petrolina, Pernambuco. Brasil 2Universidade Federal do Vale do Sao Francisco, Nucleo de Biotecnologia, Petrolina, Pernambuco. Brasil 3Universidade Federal do Vale do Sao Francisco, Laboratorio de Espectroscopia de Impedancia e Materiais Organicos, Petrolina, Pernambuco. Brasil |
| Año: | 2022 |
| Volumen: | 58 |
| País: | Brasil |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Experimental, aplicado |
| Resumen en inglés | Melatonin (MLT) reportedly reduces side effects associated with certain antineoplastic agents. Accordingly, we investigated the effect of MLT on cisplatin (CP)-induced gastric emptying (GE) delay. Mice were intraperitoneally pretreated with vehicle (ethanol 5%; control group), MLT (5, 10, or 20 mg/kg), or N-acetylcysteine (NAC; 150 mg/kg), followed by CP treatment (5 mg/kg). Pharmacological modulation was analyzed using relevant receptor antagonists (luzindole: non-selective MT1/MT2 antagonist; 5 mg/kg or 4-P-PDOT: selective MT2 antagonist; 4 mg/kg) before treatment with MLT plus CP. All treatments were performed once daily for three days. GE was assessed using phenol red. Gut morphology was examined using scanning electron microscopy and optical microscopy. Compared with the control, CP decreased GE. Pretreatment with NAC and MLT (5 and 10 mg/kg) did not prevent CP-induced gastric dysmotility; however, pretreatment with 20 mg/kg MLT prevented this effect. In addition, luzindole and 4-P-PDOT suppressed MLT-mediated gastroprotection against cytotoxic effects of CP. CP caused degeneration of the gut mucosa, which was attenuated by MLT treatment. Thus, 20 mg/kg MLT prevented the GE delay and decreased CP-induced adverse effects on the gut mucosa. In addition, the gastroprotective activity was mediated via the MT2 receptor |
| Disciplinas: | Medicina |
| Palabras clave: | Farmacología, Oncología, Quimioterapia, Cisplatino, Efectos adversos, Motilidad intestinal, Melatonina |
| Keyword: | Pharmacology, Oncology, Chemotherapy, Cisplatin, Adverse effects, Intestinal motility, Melatonin |
| Texte intégral: | Texto completo (Ver HTML) Texto completo (Ver PDF) |
